Insilco based drug discovery
The pharmaceutical business in the global environment will have to be competitive. The central activities of pharmaceutical research are drug design and delivery. Drug designs the design or discovery of molecular structures which fit certain receptor sites in the protein. The role of computational modeling in drug design is highly developed, dominated by a mature methodology involving techniques such as Quantitative Structure Activity Relationships (QSAR), Ligand Docking, and Molecular Dynamics.
The objective of the Insilco drug designing is to build models of metabolic systems and simulate and analyze them for the rational design of more efficacious drugs. The focus for the research is many dangerous diseases which are of world's most significant health concerns.
This Insilco drug designing will focus on the drug discovery pipeline and how systems biology can play a role in each of the steps, particularly in the identification and validation of new drug targets. Target validation has traditionally been a laborious process, dependent on animal models and in vivo experiments. Insilco drug designing has developed Target on viruses, an Insilco target validation tool for many bacterial, viral based diseases.
The computational model for drug designing makes industry’s R&D faster a bit. This new role for informatics—at the core of a new pharmaceutical R&D process focused on delivering more and better drugs in a shorter time period. Human ingenuity should again prove to be the pharmaceutical industry’s ultimate driver in creating treatment for poorly or previously untreated diseases.